How much protein do you need on a GLP-1? What the clinical trials actually show

What's less settled than the protein target itself is the number everyone repeats to explain why it matters: "up to 40% of weight lost on a GLP-1 can be muscle." That figure is on this site too. It's directionally reasonable, but the actual research tells a more interesting story than one round number — and understanding it explains why two people on the same medication can end up with very different outcomes.

What the trials actually found

The clearest single-trial data point comes from a body-composition substudy of STEP 1, the pivotal trial for semaglutide 2.4mg (Wegovy). Researchers scanned 140 participants with DEXA — the gold-standard body composition measurement — before and after 68 weeks of treatment. The semaglutide group lost 15.0% of body weight, made up of a 19.3% reduction in fat mass and a 9.7% reduction in lean body mass.

That's one data point. It's not the whole picture. A 2024 review in Diabetes, Obesity and Metabolism — specifically about lean mass changes on GLP-1 therapies — pulled together findings across many trials and found something that gets left out of the "40%" shorthand: lean mass accounted for anywhere from 15% to over 60% of total weight lost, depending on the study.

That's a wide range. The review's authors point to population differences, which specific drug was used, and comorbidities as likely explanations — but the practical takeaway is that the number isn't fixed. It moves based on what a person does during treatment, not just which medication they're on.

Why the range is so wide

Two things show up consistently in the research as predictors of where someone lands in that range:

Protein intake. The GLP-1 literature doesn't stand alone here — it sits on top of a much larger body of research on protein and muscle preservation during any weight loss, GLP-1 or not. A systematic review and meta-analysis of protein intake in adults with overweight or obesity found that higher protein diets consistently preserved more muscle mass, strength, and physical function during weight loss than lower-protein diets, across young, middle-aged, and older adults alike.

Resistance training. A small 2025 case series specifically in GLP-1 patients — three people on semaglutide or tirzepatide, each doing resistance training 3–5 days a week while eating 1.6–2.3g of protein per kilogram of fat-free mass — found lean tissue was preserved in all three, and actually increased in two of them, despite significant fat loss. It's a case series, not a randomized trial, so it can't prove cause and effect on its own. But it's directionally consistent with the broader protein-and-training literature, and a larger randomized controlled trial (called LEAN-PREP) designed specifically to test resistance exercise and protein during semaglutide and tirzepatide therapy is now underway.

Put together: the studies showing lean mass loss at the low end of that 15–60% range tend to involve more protein and more resistance training. The studies at the high end tend not to. That's not a guarantee for any one person, but it's the most actionable signal in the research — and it's the same lever regardless of which GLP-1 you're on.

What this means for your number

None of this changes the target: 1.2–1.6g/kg/day, same as before. What it changes is the stakes. If lean-mass loss can run as high as 60% of total weight lost in some circumstances — and as low as 15% in others — protein intake and resistance training aren't a nice-to-have on top of the medication. They're most of the variance the research can actually explain.

Calculate your exact target →

By medication

Dose and drug class shift the specifics. See the full breakdown for yours:

• Protein on Ozempic →
• Protein on Wegovy →
• Protein on Mounjaro →
• Protein on Zepbound →

Sources

• Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024.
• Wharton S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Association of British Clinical Diabetologists.
• Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. 2025.
• LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
• Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: A systematic review and meta-analysis.

This article summarizes published research for general education. It is not medical advice — talk to your prescriber or a Registered Dietitian about what's right for your situation.